四氢生物蝶呤模拟物和拮抗剂：一类新兴的用于癌症治疗的Bcl-2蛋白调节剂。 - Suppr

BH4-mimetics and -antagonists: an emerging class of Bcl-2 protein modulators for cancer therapy.

作者信息

Nougarède Adrien, Rimokh Ruth, Gillet Germain

机构信息

Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France.

出版信息

Oncotarget. 2018 Oct 19;9(82):35291-35292. doi: 10.18632/oncotarget.26250.

DOI:10.18632/oncotarget.26250

PMID:30450157

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6219674/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/906a/6219674/68a2fedd83c3/oncotarget-09-35291-g001.jpg

相似文献

BH4-mimetics and -antagonists: an emerging class of Bcl-2 protein modulators for cancer therapy.

Oncotarget. 2018 Oct 19;9(82):35291-35292. doi: 10.18632/oncotarget.26250.

Non-canonical roles of Bcl-2 and Bcl-xL proteins: relevance of BH4 domain.

Carcinogenesis. 2017 Jun 1;38(6):579-587. doi: 10.1093/carcin/bgx016.

BH4 domain of bcl-2 protein is required for its proangiogenic function under hypoxic condition.

Carcinogenesis. 2013 Nov;34(11):2558-67. doi: 10.1093/carcin/bgt242. Epub 2013 Jul 8.

The conserved N-terminal BH4 domain of Bcl-2 homologues is essential for inhibition of apoptosis and interaction with CED-4.

EMBO J. 1998 Feb 16;17(4):1029-39. doi: 10.1093/emboj/17.4.1029.

A double point mutation at residues Ile14 and Val15 of Bcl-2 uncovers a role for the BH4 domain in both protein stability and function.

FEBS J. 2018 Jan;285(1):127-145. doi: 10.1111/febs.14324. Epub 2017 Dec 2.

BH4 domain of Bcl-2 as a novel target for cancer therapy.

Drug Discov Today. 2016 Jun;21(6):989-96. doi: 10.1016/j.drudis.2015.11.008. Epub 2015 Nov 26.

A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum.

Biochim Biophys Acta. 2014 Oct;1843(10):2240-52. doi: 10.1016/j.bbamcr.2014.04.017. Epub 2014 Apr 21.

BH4-domain peptide from Bcl-xL exerts anti-apoptotic activity in vivo.

Oncogene. 2003 Nov 20;22(52):8432-40. doi: 10.1038/sj.onc.1207180.

The BH4 domain of Bcl-2 orthologues from different classes of vertebrates can act as an evolutionary conserved inhibitor of IP receptor channels.

Cell Calcium. 2017 Mar;62:41-46. doi: 10.1016/j.ceca.2017.01.010. Epub 2017 Jan 25.

Exogenous BH4/Bcl-2 peptide reverts coronary endothelial cell apoptosis induced by oxidative stress.

J Vasc Res. 2004 Mar-Apr;41(2):202-7. doi: 10.1159/000077408. Epub 2004 Mar 19.

引用本文的文献

Nrh L11R single nucleotide polymorphism, a new prediction biomarker in breast cancer, impacts endoplasmic reticulum-dependent Ca traffic and response to neoadjuvant chemotherapy.

Cell Death Dis. 2023 Jul 1;14(6):392. doi: 10.1038/s41419-023-05917-7.

Novel BH4-BCL-2 Domain Antagonists Induce BCL-2-Mediated Apoptosis in Triple-Negative Breast Cancer.

Cancers (Basel). 2022 Oct 26;14(21):5241. doi: 10.3390/cancers14215241.

BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models.

Cell Death Dis. 2020 Sep 17;11(9):769. doi: 10.1038/s41419-020-02944-6.

Creating a New Cancer Therapeutic Agent by Targeting the Interaction between Bcl-2 and IP Receptors.

Cold Spring Harb Perspect Biol. 2019 Sep 3;11(9):a035196. doi: 10.1101/cshperspect.a035196.

Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy.

Int J Mol Sci. 2018 Dec 8;19(12):3950. doi: 10.3390/ijms19123950.

本文引用的文献

Reciprocal sensitivity of diffuse large B-cell lymphoma cells to Bcl-2 inhibitors BIRD-2 versus venetoclax.

Oncotarget. 2017 Dec 4;8(67):111656-111671. doi: 10.18632/oncotarget.22898. eCollection 2017 Dec 19.

Breast Cancer Targeting through Inhibition of the Endoplasmic Reticulum-Based Apoptosis Regulator Nrh/BCL2L10.

Cancer Res. 2018 Mar 15;78(6):1404-1417. doi: 10.1158/0008-5472.CAN-17-0846. Epub 2018 Jan 12.

BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice.

J Exp Med. 2016 Aug 22;213(9):1705-22. doi: 10.1084/jem.20150983. Epub 2016 Jul 25.

A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2.

Oncotarget. 2015 Sep 29;6(29):27388-402. doi: 10.18632/oncotarget.4489.

IP3R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP3R-derived peptide targeting the BH4 domain of Bcl-2.

Cell Death Dis. 2013 May 16;4(5):e632. doi: 10.1038/cddis.2013.140.

Mechanisms of action of Bcl-2 family proteins.

Cold Spring Harb Perspect Biol. 2013 Apr 1;5(4):a008714. doi: 10.1101/cshperspect.a008714.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

BH4-mimetics and -antagonists: an emerging class of Bcl-2 protein modulators for cancer therapy.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献